Form 4 for CGON CG Oncology, Inc.
Accepted 2026-06-25 16:30:02 ET · period of report 2026-06-24 · accession 0001193125-26-282861 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-06-25 16:30 | 2026-06-24 | CGON | POST LEONARD E | Dir | M - OptEx | $0.6 | +5,000 | 5,000 | New | +$3,000 |
| DT | 2026-06-25 16:30 | 2026-06-24 | CGON | POST LEONARD E | Dir | S - Sale+OE | $70.00 | -5,000 | 0 | -100% | -$350.0K |
| DT | 2026-06-25 16:30 | 2026-06-24 | CGON | POST LEONARD E | Dir | M - OptEx | $0.00 | -5,000 | 106.1K | -5% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-24 | M | A | 5,000 | $0.6 | 5,000 | D | — | — | |
| 2 | Common | Common Stock | 2026-06-24 | S | D | 5,000 | $70.00 | 0 | D | — | — | (F1) The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2026. |
| 3 | Derivative | Director Stock Option (right to buy) | 2026-06-24 | M | D | 5,000 | $0.00 | 106,077 | D | $0.6 · — to 2028-07-08 | 5,000 Common Stock | (F2) Fully vested |